Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 9Recruiting 8Withdrawn 2Terminated 2Unknown 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Urinary Bladder Neoplasms 4Rectal Neoplasms 4Glioblastoma 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Radiation Injuries 2Prostatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lung Neoplasms 2Invasive Breast Cancer 2Head and Neck Neoplasms 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Tuberous Sclerosis 1Thyroid Neoplasms 1Stomach Neoplasms 1Stomach Diseases 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Respiratory Aspiration 1Prostate Adenocarcinoma 1Premenopausal Breast Cancer 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1

Interventions

Radiotherapy 11pembrolizumab 10Nivolumab 10Doxorubicin 10Magnetic Resonance Spectroscopy 9Specimen Handling 8Cyclophosphamide 8Biopsy 7X-Rays 6Ipilimumab 6Radiation 5Phantoms, Imaging 5Ifosfamide 5talimogene laherparepvec 4cabozantinib 4Nuclear Medicine Department, Hospital 4Irinotecan 4tazemetostat 3selpercatinib 3pazopanib 3liposomal doxorubicin 3fludarabine 3Temozolomide 3Etoposide 3ulixertinib 2tislelizumab 2tipifarnib 2palbociclib 2larotrectinib 2ivosidenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Sarcoma × Surgical Procedures, Operative × Clear all
NCT06660810 2026-01-15

Neoadjuvant Intralesional Injection of Talimogene Laherparepvec

University of Iowa

Phase 2 Active not recruiting
2 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡